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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2016, TaiwanBackground: Chylothorax is a rare condition among neonates, although it is considered clini-
cally significant, as it is difficult to manage in these patients. In addition, the course of chy-
lothorax varies widely. Therefore, we aimed to elucidate the clinical features and effect of
prenatal therapy on the prognosis of congenital chylothorax in neonates.
Methods: We retrospectively reviewed the medical records of all infants with congenital chy-
lothorax who were admitted to National Taiwan University Hospital, Taipei, Taiwan between
January 2000 and December 2012. Their demographic characteristics, as well as their ante-
natal, perinatal, and postnatal information, were collected for our analysis of the mortality
risk.
Results: We found 29 infants who were diagnosed with congenital chylothorax during the study
period. The median gestational age at birth was 34 weeks (range, 28e41 weeks), and 71% of
the infants presented with hydrops fetalis. Most cases of congenital chylothorax were bilateral
(bilateral: 86.2%, unilateral: 13.79%), and the overall survival rate was 59.6%. Among the cases
with a prenatal diagnosis at  34 weeks of gestation, infants who received prenatal therapy
had a significantly higher survival rate, compared to infants who did not receive prenatal ther-
apy (76.9% vs. 11%, respectively; p Z 0.008).
Conclusion: We found that infants whose chylothorax was diagnosed  34 weeks of gestation,
and who subsequently received prenatal therapy, experienced a better perinatal condition and
exhibited improved postnatal outcomes.
Copyright ª 2016, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.of Pediatrics, National Taiwan University Hospital, Number 8, Chung-Shan South Road, Taipei 100,
w (H.-C. Chou).
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128 C.-J. Lee et al1. IntroductionPleural effusion is the accumulation of fluid in the pleural
cavity, and can be caused by chylothorax, hemothorax,
empyema, hydrothorax, or leakage of central-line fluid.
Although pleural effusion is rare in the neonatal period,
chylothorax (which is characterized by chyle collection) is
the most common etiology.1e4 These cases can be acquired
as postoperative or iatrogenic complications, as isolated
congenital causes, or in association with other congenital
abnormalities, and subsequently result in chyle accumula-
tion in the pleural space.5e7 The severity of the clinical
manifestation depends on the amount of chyle accumu-
lated. Some infants remain asymptomatic or experience
only mild respiratory distress, while others present as
potentially life-threatening conditions that require urgent
drainage and other resuscitative management immediately
after birth.6e8 Unfortunately, prolonged severe fetal
pleural effusion can compromise normal lung maturation
and progress to fetal hydrops, ultimately resulting in pre-
mature birth and pulmonary hypoplasia, with a high rate of
intrauterine death and perinatal mortality.
No consensus has been reached regarding the manage-
ment of congenital chylothorax, although it is commonly
accepted that respiratory and life support, diet restriction,
and pharmacological and surgical interventions are needed.
However, the specific methods or extent of the manage-
ment differ among neonatal care units. In this setting,
prenatal therapies for congenital chylothorax, such as
transabdominal thoracocentesis, in utero pleurodesis, or
the placement of a thoracoamniotic shunt, may alter the
natural course and improve the perinatal outcome.8e11
Therefore, we conducted the present study to clarify
whether prenatal therapy could improve the survival out-
comes of infants with congenital chylothorax.
2. Methods
This retrospective study was performed in the neonatal
intensive care unit (NICU) at the National Taiwan University
Hospital, which is a tertiary perinatal and neonatal unit in
Northern Taiwan. The study design was reviewed andFigure 1 Flow chart of the enrollment process. We identified 4
congenital chylothorax and were diagnosed before 34 weeks of geapproved by the Research Ethics Board Committee of Na-
tional Taiwan University Hospital.
We retrospectively evaluated all neonates who were
admitted to the NICU between January 2000 and December
2012 with a diagnosis of any-cause congenital pleural effu-
sion or hydrops fetalis. We also evaluated cases that had
undergone thoracocentesis or the insertion of an intercostal
catheter for fluid drainage during hospitalization. From
these cases, we included only neonatal cases with a
confirmed diagnosis of congenital chylothorax (Figure 1). We
then extracted various clinical data from the patients’
medical records, including sex, birth body weight, gesta-
tional age, time of the diagnosis, etiology of the pleural
effusion, underlying disease, fetal therapy, perinatal or
postnatal management, respiratory condition, site and
duration of the pleural effusion, morbidity, and mortality.
The diagnosis of pleural effusion was made antenatally
via ultrasonography or postnatally via chest radiography or
ultrasonography. Congenital pleural effusion was defined as
pleural effusion that was diagnosed antenatally or at birth.
The antenatal therapies included transabdominal thor-
acocentesis, in utero pleurodesis, and the placement of a
thoracoamniotic shunt. The attending obstetrician made a
personal decision to determine which patients received
antenatal therapy. Hydrops fetalis was defined as a fetus
with two or more sonographic findings of excess fluid accu-
mulated in the form of ascites, pleural or pericardial effu-
sions, skin edema, placental edema, or polyhydramnios.12
The presence of chylothorax was confirmed based on the
criteria that were proposed by Bu¨ttiker et al13: triglyceride
levels of > 110 mg/dL, or a total white blood cell count >
1000/mL with a predominance of lymphocytes. We followed
up these cases until they discharged and the mortality cases
referred to the cases who did not survive at discharge.2.1. Statistical analysis
Statistical comparisons were performed using the Mann-
Whitney U test for continuous variables and Fisher’s exact
test for categorical variables. Multivariate logistic regres-
sion analysis was used to calculate the adjusted odds ratios
for mortality. All statistical tests were two-tailed and4 neonates with congenital pleural effusion. Most infants had
station.
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significance. The data were analyzed using SPSS version
12.0 (SPSS Inc., Chicago, IL, USA).3. Results
During the study period, we identified 44 neonates with
congenital pleural effusion (Figure 1). Most cases involved
congenital chylothorax (n Z 29, 66%), although other cau-
ses of the congenital pleural effusion included severe
anemia, twin-to-twin transfusion syndrome, complicated
meconium peritonitis, and delayed lung fluid absorption.
Among the 29 infants with congenital chylothorax, the
median gestational age at diagnosis was 30 weeks (range,
17e38 weeks), and the median gestational age at birth was
34 weeks (range, 28e41 weeks). Hydrops fetalis was
observed during the prenatal examination in 71% of the
infants with congenital chylothorax, and most cases
involved bilateral pleural effusion (86.2%). Most of the
included infants were male (n Z 18, 62.1%), and five in-
fants had chromosomal anomalies, including trisomy 21,
Alagille syndrome, Noonan syndrome, 47XYY, and chromo-
some 13 translocation. Other related conditions included
neck cystic hygroma, lung sequestration, fetal junctional
rhythm, and placental chorioangioma. Intrauterine in-
terventions were performed for 16 infants (55.2%).
After birth, 22/29 infants (75.9%) with congenital chy-
lothorax required ventilator support, including a high-
frequency ventilator (n Z 14), inhaled nitric oxideTable 1 Demographic data and clinical variables in surviving and
gestation.
Number Surv
(n Z
Perinatal factors
Gestational age at diagnosis (mean, wk) 27
Prenatal therapy (%) 90.9
Hydrops fetalis (%) 25.8
Bilateral pleural effusion (%) 81.8
Postnatal factors
Gestational age at delivery (mean, wk) 34
Birth body weight (g) 2,72
1-Min Apgar score (mean) 5
5-Min Apgar score (mean) 7
Thoracocentesis after birth (%) 82
Chest tube insertion after birth (%) 55
Pneumothorax (%) 9
Associated anomalies (%) 36
Ventilator parameters
Ventilator use (%) 64
OI at admission 16
AaDO2 at admission 316
OI at second arterial blood gas test 15
AaDO2 at second arterial blood gas test 278
OI at 24 h 7
AaDO2 at 24 h 146
*p < 0.05.
AaDO2 Z alveolar arterial oxygen partial pressure gradient; OI Z oxy(n Z 2), and extracorporeal support (n Z 1). Conservative
therapy (delayed enteral feeding) was provided to all in-
fants, and the infants were then provided with a diet that
was rich in medium-chain triglycerides. The adjunctive
medical approach (octreotide) was administrated to four
infants, with the dosage titrated according to their chest
drainage (maximum dose: 10 mg/kg/hour in two infants).
One infant underwent surgical pleurodesis due to prolonged
lymphatic leakage.
Among these 29 infants, we compared the parameters
between surviving and non-surviving infants. We found that
the surviving group had significant older gestational age at
delivery (pZ 0.013), larger birth body weight (pZ 0.046),
less pneumothorax (p Z 0.038), less hydrops (p Z 0.009),
and more prenatal intervention percentage (p Z 0.01).
Among the cases of congenital chylothorax, 12 (41.4%) of
the neonates died before discharge; most were diagnosed
before 34 weeks of gestation. One infant had chylothorax
complicated with hydrops fetalis at 35 weeks of gestation,
and was delivered immediately, without prenatal therapy.
He also had bilateral hydronephrosis and died at the age of
32 days, due to Acinetobacter baumannii sepsis compli-
cated by acute renal failure.
In addition, according to the algorithm proposed by
Rustico et al,10 prenatal intervention could be conducted to
a fetus with progressed pleural effusion identified before 34
weeks of gestation. Therefore, to analyze the related sur-
vival factors, we focused on the cases of chylothorax that
were diagnosed at  34 weeks of gestation (nZ 22) (Table
1). No differences were observed in gestational age, birthnonsurviving infants with a prenatal diagnosis  34 weeks of
iving Nonsurviving p
11) (n Z 11)
27 0.974
1 27.27 0.008*
4 40.60 0.09
2 100 0.214
32 0.176
1 2,463 0.25
1 0.001*
2 0.001*
100 0.476
72.73 0.659
63.64 0.063
27 1.000
100 0.09
75 0.005*
571 0.027
65 0.002*
576 0.001*
63 0.04*
643 0.04*
gen index.
Table 2 Demographic data and clinical variables in infants with a prenatal diagnosis  34 weeks of gestation with or without
prenatal therapy.
Prenatal therapy With Without p
Characteristics (n Z 13) (n Z 9)
Perinatal factors
Gestational age at diagnosis (mean, wk) 25 29 0.963
Hydrops fetalis (%) 76.92 88.89 0.616
Bilateral pleural effusion (%) 84.62 100 0.24
Postnatal factors
Gestational age at delivery (mean, wk) 32 33 0.638
Birth body weight (g) 2448.46 2798.89 0.404
Male sex (%) 23.08 66.67 0.387
1-Min Apgar score (mean) 4 1 0.007*
5-Min Apgar score (mean) 6 2 0.005*
Thoracocentesis after birth (%) 85 100 0.494
Chest tube insertion after birth (%) 69 56 0.662
Pneumothorax (%) 8 78 0.007*
Ventilator parameters
Ventilator use (%) 23 89 0.616
OI at admission 28 75 0.017*
AaDO2 at admission 375 557 0.329
OI at second arterial blood gas test 23 69 0.009*
AaDO2 at second arterial blood gas test 339 575 0.009*
OI at 24 h 16 51 0.245
AaDO2 at 24 h 208 646 0.121
Survival to discharge (%) 76.9 11 0.008*
*p < 0.05.
AaDO2 Z alveolar arterial oxygen partial pressure gradient; OI Z oxygen index.
Table 3 Multivariate logistic regression analysis of pre-
disposing factors and survival outcome in infants with pre-
natal diagnosed at  34 weeks of gestation.
Odds
ratio
95% Confidence
interval
p
Gestational age
at birth
0.788 0.525e1.182 0.250
Birth body weight 1.002 0.999e1.005 0.113
Gestational age
at diagnosis
1.167 0.819e1.663 0.394
Prenatal therapy 0.004 0.000e0.333 0.014
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lies or other association, and the use of thoracocentesis or
chest tube insertion after birth when we compared the
surviving and nonsurviving infants. The median age for pa-
tients who died was 1 day (1e28 days). Among the surviving
infants, 90.91% have received prenatal therapy, compared
to 27.3% of the infants in the non-survival group
(p Z 0.008). The Apgar scores at the 1st and 5th minutes,
oxygen index (1st day and at 24 hours), and alveolar arterial
oxygen partial pressure gradient (1st day and at 24 hours)
were also significantly better in the surviving group. A trend
towards a lower prevalence of hydrops fetalis and pneu-
mothorax was observed in the surviving group. To further
confirm that prenatal intervention can improve survival in
infants with congenital chylothorax diagnosed at  34
weeks of gestational age, we divided our cases into two
groups according to receiving prenatal therapy or not. We
found no statistically significant differences in their pre-
natal characteristics, such as gestational age at diagnosis
and birth, sex, birth body weight, presence of hydrops
fetalis, and site of the pleural effusion (Table 2). However,
the infants who received prenatal therapy exhibited
significantly better 1st and 5th minute Apgar scores, oxygen
indexes, and alveolar arterial oxygen partial pressure gra-
dients. The survival rate was also significantly higher among
the infants who received prenatal therapy, compared with
that among the infants who did not receive prenatal ther-
apy (76.9% vs. 11%, respectively; p Z 0.008). After logistic
regression analysis, we observed that fetal therapy could
independently improve the perinatal outcome ofchylothorax that was diagnosed before 34 weeks of gesta-
tion (odds ratio: 0.004, 95% confidence interval:
0.000e0.33, p Z 0.014) (Table 3).4. Discussion
In the present study, we found that infants who had been
diagnosed with congenital chylothorax at  34 weeks of
gestation and who subsequently received prenatal therapy
exhibited improved Apgar scores during the perinatal
period, better ventilator parameters after admission, a
lower incidence of pneumothorax, and a better survival
rate. Therefore, fetuses that are diagnosed with pleural
effusion should be evaluated comprehensively, as for in-
fants with hydrops, to determine the etiology of the
Prenatal therapy in congenital chylothorax 131effusion, such as congenital infections, chromosomal
anomaly, any associated anomalies, and the possibility of
fetal anemia.1,9,12
Congenital chylothorax is a rare disease, and it is the
most common cause of congenital pleural effusion.1e4,7 It is
consistent with our finding that 66% cases with congenital
pleural effusion had chylothorax. In addition, previous
studies have reported a predominance of male patients,1,7
which is also supported by our results. Furthermore, we
found that most infants presented with bilateral effusion,
and this finding has also been reported previously.5,6 How-
ever, we found that right-sided and left-sided chylothorax
was evenly distributed in our study, although previous
studies have reported that right-sided chylothorax was
more common in unilateral presentations, because of the
anatomy of the thoracic duct.1,5,6 This discrepancy may be
related to the small number of infants in our study who
presented with unilateral collection.
Congenital chylothorax may occur alone or in combina-
tion with other genetic syndromes, including Down syn-
drome, Noonan syndrome, and Turner syndrome.2,7,8,14 We
observed chromosomal anomalies in five of our patients,
including Down syndrome, Noonan syndrome, Alagille syn-
drome, chromosome 13 translocation, and 47 XYY. In
addition, other studies have reported several associations
including congenital pulmonary lymphangiectasis and cystic
hygroma.6,7,15e18 In the present study, we also observed
associations with neck cystic hygroma, lung sequestration,
junctional rhythm, and placental chorioangioma.
Many factors have been reported to be associated with a
poor prognosis after antenatal detection of fetal pleural
effusion.9 These factors include an abnormal karyotype,
which is related to subsequent fetal death,14,19,20 and
premature delivery or the presence of hydrops fetalis.9,
21,22 However, Weber and Philipson23 reported that the
use of antenatal therapy is associated with positive out-
comes in cases of isolated fetal pleural effusion. In the
present study, we also found that older gestation age at
delivery, the absence of hydrops, use of antenatal therapy,
and the absence of pneumothorax were associated positive
outcomes. Although our focus was on infants whose chylo-
thorax was detected at  34 weeks of gestation, only
prenatal therapy remained an independent factor after the
multivariate analysis. Furthermore, when the diagnosis was
made after 34 weeks of gestation, no factor significantly
affected the patients’ prognosis.
The benefits of antenatal therapy appear to be the
facilitation of neonatal resuscitation, resolution of fetal
hydrops, and prevention of pulmonary hypoplasia.24 Among
infants with congenital chylothorax, the antenatal therapy
options include repeated transabdominal thoracocentesis,
in utero pleurodesis, or the placement of a thor-
acoamniotic shunt, although the comparative efficacies of
these therapies remain controversial.10,11,25,26 Rustico
et al10 proposed a management algorithm for apparent
primary fetal pleural effusion. If the pleural effusion is
confirmed at > 34 weeks of gestation, they suggest imme-
diate thoracocentesis and delivery. However, when the
pleural effusion is identified before 34 weeks of gestation,
presenting with mild-to-moderate unilateral effusions
without hydrops, they suggest serial weekly ultrasonogra-
phy follow ups to determine if spontaneous regressionoccurs. In cases where the pleural effusion progresses or
where hydrops develops, they suggest serial thoracocent-
esis or thoracoamniotic shunting. In the present study, we
confirmed that antenatal therapy significantly benefited
infants with congenital chylothorax that was identified at 
34 weeks of gestation. In this context, thoracocentesis
could be considered immediately before delivery, or as an
ex utero intrapartum treatment, to decrease the cardio-
pulmonary compromise that is experienced after termi-
nating umbilical support.
There is onemajor limitation toconsiderwhen interpreting
our findings, which is that the present study was a single-
center, nonrandomized, noncontrolled retrospective study of
infants who had been admitted to our NICUwith a diagnosis of
congenital chylothorax. Therefore, cases of intrauterine
death (either because of a worsening condition or artificial
abortion) were not included. In addition, the attending
obstetrician made a personal decision to determine which
patients received antenatal therapy. These may have biased
our results. However, despite this limitation, our article de-
scribes the perinatal outcomes in infants with congenital
chylothorax who were diagnosed at  34 weeks of gestation.
In conclusion, the clinical condition of congenital chy-
lothorax can vary in both the prenatal and postnatal pe-
riods. However, we found that infants whose chylothorax
was diagnosed at  34 weeks of gestation, and who sub-
sequently received prenatal therapy, experienced better
perinatal condition and exhibited improved postnatal out-
comes. However, further studies are needed to define the
ideal algorithm for guiding the management of congenital
chylothorax in the prenatal and neonatal periods.
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